Evidence map›Paper›PMID 41069042›Full record

ArticleJournal of Alzheimer's disease : JAD2025

Timing of neurorehabilitation and subsequent Alzheimer's disease risk in patients with moderate to severe traumatic brain injury: A nationwide retrospective cohort study in the United States.

Austin A Kennemer, Zhenxiang Gao, Pamela B Davis, David C Kaelber, Rong Xu

Abstract read
In one paragraph

Article in Journal of Alzheimer's disease : JAD, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Austin A KennemerCenter for Artificial Intelligence in Drug Discovery, Case Western Reserve University School of Medicine, Cleveland, OH, USA.
Zhenxiang GaoCenter for Artificial Intelligence in Drug Discovery, Case Western Reserve University School of Medicine, Cleveland, OH, USA.
Pamela B DavisCenter for Community Health Integration, Case Western Reserve University School of Medicine, Cleveland, OH, USA.
David C KaelberCenter for Clinical Informatics Research and Education, The MetroHealth System, Cleveland, OH, USA.
Rong XuCenter for Artificial Intelligence in Drug Discovery, Case Western Reserve University School of Medicine, Cleveland, OH, USA.

Funding

Clinical and Translational Science Collaborative of Northern Ohio, Catalyzing Linkages to Equity in Health (CLE Health)UM1TR004528 · NCATS · CASE WESTERN RESERVE UNIVERSITY · PI GRACE A MCCOMSEY · 2023 to 2026
$32.1M
Combine computational prediction, network analysis and genetic screening in C elegans to uncover neurodegenerative causes in Alzheimer's DiseaseR01AG061388 · NIA · CASE WESTERN RESERVE UNIVERSITY · PI CHEN, SHU G., XU, RONG · 2018 to 2022
$3.4M
An Integrated Reverse Engineering Approach Toward Rapid drug Re positioning for Alzheimer's DiseaseR01AG057557 · NIA · CASE WESTERN RESERVE UNIVERSITY · PI XU, RONG · 2017 to 2021
$2.8M
Collision of Alzheimers disease and COVID-19 pandemic in the United States: risks, outcomes, disparities and treatmentsRF1AG076649 · NIA · CASE WESTERN RESERVE UNIVERSITY · PI DAVIS, PAMELA B, XU, RONG · 2022 to 2022
$2.3M
Construct large-scale phenomes of disease and drugs and develop data-driven systems approaches to understand genetic links between Alzheimer's disease and Neuropsychiatric symptomsR56AG062272 · NIA · CASE WESTERN RESERVE UNIVERSITY · PI XU, RONG · 2018 to 2019
$1.6M
Collision of Alzheimers disease and COVID-19 pandemic in the United States: risks, outcomes, disparities and treatmentsR01AG076649 · NIA · CASE WESTERN RESERVE UNIVERSITY · PI Rong Xu · 2025 to 2026
$1.6M
Characterize multifaceted interactions between COVID-19 and alcohol use disorder based on real-time analysis of electronic health records of 62 million adult patientsR01AA029831 · NIAAA · CASE WESTERN RESERVE UNIVERSITY · PI DAVIS, PAMELA B, XU, RONG · 2021 to 2023
$1.1M
Medical Student Summer Research Program in Aging and Alzheimer's disease (MSSRPA)T35AG086098 · NIA · CASE WESTERN RESERVE UNIVERSITY · PI Pauline Terebuh · 2024 to 2026
$278k
NCATS NIH HHS UM1 TR004528NIAAA NIH HHS R01 AA029831NIA NIH HHS R01 AG057557NIA NIH HHS R01 AG061388NIA NIH HHS R01 AG076649NIA NIH HHS R56 AG062272NIA NIH HHS RF1 AG076649NIA NIH HHS T35 AG086098
6 · The paper itself

Abstract

BackgroundTraumatic brain injury (TBI) is associated with an increased risk of Alzheimer's disease (AD). It is unknown if prompt neuro-rehabilitative treatment following moderate or severe TBI mitigates this risk compared with delayed treatment.ObjectiveTo determine whether immediate neuro-rehabilitative treatment following moderate or severe TBI reduces the risk of AD and related cognitive outcomes compared with delayed treatment.MethodsWe conducted a retrospective cohort using the TriNetX Analytics Platform, which includes health records from over 100 million US patients. Adults aged 50-90 years with moderate or severe TBI were included if they received immediate treatment (within 1 week) or delayed treatment (>1 week). Outcomes were AD risk at 3- and 5-year follow-up, with additional outcomes of mild cognitive impairment (MCI), dementia, and AD-related medication prescriptions. Cox proportional hazards models were applied to propensity score-matched cohorts, and hazard ratios (HRs) with 95% confidence intervals (CIs) were calculated.ResultsOf 37,081 eligible patients, 17,636 remained after propensity score matching. Immediate treatment was associated with lower AD risk compared with delayed treatment (HR, 0.59; 95% CI, 0.41-0.86 at 3 years; HR, 0.70; 95% CI, 0.52-0.94 at 5 years). Similar risk reductions were observed for MCI, dementia, and AD-related medication use.ConclusionsImmediate treatment following moderate or severe TBI was associated with significantly reduced risk of AD and related cognitive decline. These findings suggest that prompt intervention may mitigate long-term neurodegenerative consequences of TBI.

Indexed as

Alzheimer DiseaseBrain Injuries, TraumaticNeurological RehabilitationTime-to-TreatmentAgedAged, 80 and overCognitive DysfunctionCohort StudiesFemaleHumansMaleMiddle AgedRetrospective StudiesTime FactorsUnited StatesAlzheimer's diseasedementiamild cognitive impairmenttraumatic brain injury

Identifiers

PMID41069042
PMCPMC12713421

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.